ASCO Annual Meeting

Bavencio and Inlyta together produced a promising response for some patients with renal cell carcinoma.

When combined with the IDO1 inhibitor epacadostat, Keytruda (pembrolizumab), a PD-1 inhibitor, resulted in an overall response rate (ORR) of 35 percent in patients with advanced urothelial carcinoma, according to results from the phase 1/2 ECHO-202/KEYNOTE-037 trial.

Many patients with relapsed or refractory multiple myeloma saw clinical remission with CAR T-cell therapy.

Keytruda (pembrolizumab) showed promising signs of clinical activity for patients with advanced gastric or gastroesophageal junction (GEJ), according to updated findings from KEYNOTE-059 study that were presented at the 2017 American Society for Clinical Oncology (ASCO) Annual Meeting.

Promising results from a new agent may set the stage for a new standard of care for patients with TRK fusion mutations.

An online tool helped patients to report their symptoms in real time, improving survival, according to findings presented at ASCO 2017.

According to findings presented at ASCO 2017, patients with low-risk advanced colon cancer would benefit from reducing the length of chemotherapy after surgery.

The psychotherapty known as CALM has been shown to ease depression and distress in patients with advanced cancer.

According to phase III findings presented at ASCO 2017, single radiation treatment relieved the symptoms of spinal cord compression in patients with advanced cancer as effectively as a five-day course.

There are fewer reported incidences of severe long-term side effects after childhood cancer treatment, according to a recent study.

A recent clinical trial showed that psychological intervention can ease patients' anxiety and fear of recurrence.

Progression-free survival was improved for postmenopausal women with HER2-negative advanced breast cancer when treated with Kisqali plus letrozole.